Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-26 @ 3:20 PM
NCT ID:
NCT07340502
Eligibility Criteria:
Inclusion Criteria:
* Aged between 18 and 75 years;
* Tumor stage classified as BCLC-A to -C, with no evidence of extrahepatic metastasis;
* Newly diagnosed, treatment-naïve hepatocellular carcinoma with no prior anticancer therapy;
* Child-Pugh liver function score ≤ 7;
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1;
* Absence of severe organic diseases affecting major organs (e.g., heart, lung, brain).
Exclusion Criteria:
* Decompensated liver cirrhosis;
* Concurrent other malignancies or recurrent hepatocellular carcinoma;
* Any active, known, or suspected autoimmune disease;
* History of hypersensitivity to any component of PD-1 inhibitors or lenvatinib;
* Human immunodeficiency virus (HIV) infection; or active viral hepatitis (e.g., hepatitis B or C);
* Tumor thrombus involving the inferior vena cava, hepatic veins, or the main portal vein trunk.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT07340502
Study Brief:
Protocol Section:
NCT07340502